share_log

恒瑞医药(600276.SH)：目前公司出口美国产品未受影响

Jiangsu Hengrui Pharmaceuticals (600276.SH): Currently, the company's export products to the USA are unaffected.

Gelonghui Finance ·  Jul 17 06:33

Jiangsu Hengrui Pharmaceuticals (600276.SH) stated on the interactive platform on July 17th that the FDA warning letter the company received this time is related to the previous Form 483, both of which are related to the inspection of a formulation production site in the Lianyungang area by the FDA. At present, the export of products to the United States is not affected, and there is no impact on the company's other production sites, which will not have a significant impact on the company's performance. In response to the improvement suggestions raised by the FDA in this warning letter, the company will actively organize internal and external experts and third-party consulting institutions to implement relevant suggestions, maintain close communication with the FDA, and strive to close the warning letter as soon as possible.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment